Skip to main content
. 2022 Jan 31;14(3):735. doi: 10.3390/cancers14030735

Figure 2.

Figure 2

Growth curves of C6 glioblastoma cells treated with CM from various yCD::UPRT-UC-MSCs. The course of growth/inhibition was monitored by the IncuCyte system. The cell density was followed by image scanning of the culture every 2 h over 6 d. The standard deviation was calculated for each scan. (a) Growth inhibition of C6 cells with CM from yCD::UPRT-AT-MSCs, from yCD::UPRT-UC-MSCs, and from yCD::UPRT-DP-MSCs in the presence or absence of 5-FC. (b) Growth curves of HPGC cultivated in vitro and treated with CM from yCD::UPRT-UC-MSCs in the absence or presence of 5-FC. (c) Growth inhibition of HPGC treated with CM from yCD::UPRT-DP-MSCs in the presence or absence of 5-FC. (d) Growth inhibition of HPGC treated with CM from yCD::UPRT-AT-MSCs in the presence or absence of 5-FC. 5-FC, 5-fluorocytosine; CM—conditioned medium; HPGC—human primary glioblastoma cells.